Skip to content

Kidney Transplant

  • Kidney Transplant Home
  • AlloSure
  • KidneyCare

AlloSure® is the first and only clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.

The most comprehensive tool for transplant patient surveillance. KidneyCare™ combines clinically validated AlloSure test with research use only AlloMap® Kidney and KidneyCare™ iBox, enabling you to follow trends and trajectory of kidney allograft health.

Drive better outcomes for kidney transplant recipients

Better surveillance. Better outcomes.

AlloSure® is the first non-invasive test that assesses organ health by directly measuring allograft injury, enabling better management of your kidney transplant recipients.

What is AlloSure?

AlloSure is a clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury.

  • The first and only transplant dd-cfDNA developed specifically for transplant recipients
  • Validated in prospective multicenter study
  • A non-invasive blood test that does not require prior genotyping of the donor or recipient
  • A rejection rule-out test that has high specificity

What is Cell-free DNA (cfDNA)?

  • Cell-free DNA refers to fragments of DNA in the bloodstream that originate from cells undergoing cell injury and death
  • DNA degrades into nucleosomal units consisting of ~166 bases
  • Cell-free DNA is cleared from the blood by the liver and kidney and has a half-life of about 30 minutes

AlloSure is validated and reimbursable through Medicare

  • AlloSure is validated in a 14 center prospective study
  • Broadly used in over 115 transplant centers
  • May be used in re-transplants
  • AlloSure is covered by Medicare

It’s time for innovation

The latest innovation in kidney transplant surveillance.

The most comprehensive tool for transplant patient surveillance.*

What is KidneyCare?

KidneyCare™ is the most comprehensive option for surveilling kidney allograft health, combining our clinically-validated AlloSure® Kidney dd-cfDNA test, gene expression profiling with AlloMap® Kidney, and predictive intelligence with KidneyCare™ iBox.

The latest innovation in kidney transplant surveillance can drive better outcomes for your patients.

Graft injury

  • The first non-invasive dd-cfDNA blood test that measure allograft injury
  • Clinically validated through prospective, multicenter studies
  • Developed specifically for transplants recipients

Immune quiescence

  • Gene Expression Profiling (GEP) to evaluate the level of immunoquiescence
  • Developed from 15 years of experience with AlloMap Heart

Graft survival prognosis

  • An integrative and accurate risk prediction score for kidney allograft health
  • Prognostic indication of allograft survival at 3, 5 and 7 years
  • Six center, three country validation

*KidneyCare is available for research use only and not intended for diagnostic procedures.